Capecitabine and oxaliplatin for advanced esophagogastric cancer.

摘要: For the capecitabine–fluorouracil comparison, hazard ratio for death in capecitabine group was 0.86 (95% confidence interval [CI], 0.80 to 0.99); oxaliplatin–cisplatin oxaliplatin 0.92 CI, 1.10). The upper limit of intervals both ratios excluded predefined noninferiority margin 1.23. Median survival times ECF, ECX, EOF, and EOX groups were 9.9 months, 9.3 11.2 respectively; rates at 1 year 37.7%, 40.8%, 40.4%, 46.8%, respectively. In secondary analysis, overall longer with than a 0.66 0.97; P = 0.02). Progression-free response did not differ significantly among regimens. Toxic effects fluorouracil similar. As compared cisplatin, associated lower incidences grade 3 or 4 neutropenia, alopecia, renal toxicity, thromboembolism but slightly higher diarrhea neuropathy. Conclusions Capecitabine are as effective respectively, patients previously untreated esophagogastric cancer. (Current Controlled Trials number, ISRCTN51678883.)